4,7-Bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine

Catalog No. :
ACCWZJ870
CAS No. :
1883586-01-3
Molecular Formula :
C17H25B2N3O4S
Molecular Weight :
389.10

IUPAC Name:4,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine

4,7-Bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4,7-Bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine
IUPAC Name4,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-[1,2,5]thiadiazolo[3,4-c]pyridine
Molecular FormulaC17H25B2N3O4S
Molecular Weight389.10
SMILESCC1(C)C(C)(C)OB(C2=CN=C(B3OC(C)(C)C(C)(C)O3)C4=NSN=C42)O1
InChI KeyHWSRNCFFUIMFAE-UHFFFAOYSA-N
Synonym[1,2,5]Thiadiazolo[3,4-c]pyridine, 4,7-bis(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
CAS No.1883586-01-3

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACCWZJ870 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCWZJ870 route product structure diagram
    ACCWZJ8701883586-01-3
Inquiry

2. ACCWZJ870 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACTOBU801 route compound structure diagram
    ACTOBU80173183-34-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACCWZJ870 route product structure diagram
    ACCWZJ8701883586-01-3
Inquiry

Comments (0)